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Abstract 
Background: Campylobacter jejuni is a leading bacterial cause of food-borne illness in humans. Symptoms range 
from mild gastroenteritis to dysentery. Contaminated chicken meat is the most common cause of infection. Broiler 
chickens become colonized with high numbers of C. jejuni in the intestinal tract, but do not become clinically ill. 
Vaccination of broiler chicks to control colonization by C. jejuni is challenging because immune function is limited 
in the first 2 weeks post-hatch and immune suppressive maternal antibodies are common. In addition, there is little 
time for induction of immunity, since broilers reach slaughter weight by 5–6 weeks of age. In the current study the 
immunogenicity of a C. jejuni capsular polysaccharide—diphtheria toxoid conjugated vaccine (CPSconj), administered 
subcutaneously with various adjuvants was assessed and the efficacy of vaccination for reducing cecal colonization 
after experimental challenge was evaluated by determining colony-forming units (CFU) of C. jejuni in cecal contents.
Results: The CPSconj vaccine was immunogenic when administered as three doses at 3, 4 and 5 weeks of age to 
specific pathogen free chicks lacking maternal antibodies (seroconversion rates up to 75%). Commercial broiler chicks 
(having maternal antibodies) receiving two doses of CPSconj vaccine at 7 and 21 days of age did not seroconvert 
before oral challenge at 29 days, but 33% seroconverted post challenge; none of the placebo-injected, challenged 
birds seroconverted. Vaccinated birds had significantly lower numbers of C. jejuni in cecal contents than control birds 
at necropsy (38 days of age). CFU of C. jejuni did not differ significantly among groups of birds receiving CPSconj vac-
cine with different adjuvants. In two trials, the mean reduction in CFU associated with vaccination was 0.64 log10 units.
Conclusions: The CPSconj vaccine was immunogenic in chicks lacking maternal antibodies, vaccinated beginning at 
3 weeks of age. In commercial broiler birds (possessing maternal antibodies) vaccinated at 7 and 21 days of age, 33% 
of birds seroconverted by 9 days after challenge, and there was a modest, but significant, reduction in cecal counts 
of C. jejuni. Further studies are needed to optimize adjuvant, route of delivery and scheduling of administration of this 
vaccine.
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Background
Food-borne illness due to infection with Campylobac-
ter species has been estimated to cost 1.7 billion dollars 
a year in medical costs, lost productivity and “quality-
adjusted life years” in the United States alone [1]. Reports 
compiled by the European Food Safety Authority dem-
onstrate increasing numbers of cases in humans over 
the most recent 4 years of study, in contrast to a steady 
decrease in the incidence of food-borne Salmonella 
infections [2]. Contaminated chicken meat is considered 
the most important source of infection with Campy-
lobacter in developed countries [3]. Broiler chickens 
typically become infected with Campylobacter jejuni 
after 3  weeks of age and can harbor 108 colony-form-
ing units (CFU) or more per gram of cecal contents [4] 
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by slaughter age (5–6  weeks of age). In contrast to the 
intense diarrhea and vomiting, and severe inflammation 
of intestinal tissues associated with C. jejuni infection in 
humans [5], chickens do not exhibit signs of clinical ill-
ness after colonization by C. jejuni, and inflammation of 
intestinal tissue is not evident histologically [6].
Enhanced biosecurity in poultry flocks and improved 
hygiene during processing of poultry products have 
potential to reduce contamination of meat at the retail 
level, but vaccination of broiler chickens will be needed 
in conjunction with these approaches to have a major 
impact on campylobacteriosis in humans [7]. At pre-
sent there are no licensed vaccines for reduction of col-
onization of chickens by C. jejuni [8]. Various vaccine 
approaches have been explored in experimental studies 
in chickens (reviewed by de Zoete et  al. [9]), including 
bacterins [10, 11], subunit vaccines [11], live Salmonella-
vectored vaccines [12–14], and encapsulated particle 
vaccines [8, 15], by parenteral, oral, and nasal routes. 
Putative virulence factors and potential vaccine antigens 
have included outer membrane proteins [8], flagellin [11, 
16], and transport proteins [12–14].
Recent studies have investigated the role of the capsular 
polysaccharide of C. jejuni in virulence in some species, 
and its potential as a vaccine antigen [17–20]. The capsu-
lar polysaccharide of C. jejuni 81-176 has been shown to 
mediate adherence and invasion of a human embryonic 
epithelial cell line, and to play a role in induction of diar-
rhea in a ferret model [21]. Wong et al. [22] have reported 
that modifications of the structure of the capsule of C. 
jejuni NCTC 11168 are associated with significant impair-
ment of cecal colonization of young chicks. Capsular 
polysaccharide conjugated to the diphtheria toxoid “cross-
reacting material 197” (CRM197) has been reported to be 
immunogenic in Aotus monkeys, and to protect against 
clinical diarrhea, but not colonization, following experi-
mental challenge [17]. Although purified capsular poly-
saccharides can induce protection against encapsulated 
bacteria, as T-independent antigens they typically are not 
immunogenic in young infants or chicks [23, 24], and IgG 
and memory responses are limited [25]. Conjugation of 
purified capsular polysaccharide to a protein carrier such 
as CRM197 induces T-dependent responses, and facilitates 
antibody responses at an earlier age, with isotype switch-
ing to IgG and induction of B cell memory [26].
Although vaccination of broiler chicks is an attrac-
tive approach to control colonization, there are immu-
nological and logistical barriers that must be overcome. 
Immune function is limited in the first 2  weeks post-
hatch [27, 28] and maternal antibodies to C. jejuni are 
common in the sera of young chicks [29]. In addition 
there is little time for induction of immunity, since broiler 
birds reach slaughter weight by 5–6 weeks of age.
In the current studies the immunogenicity of the cap-
sular polysaccharide of C. jejuni conjugated to CRM197 
was assessed by vaccinating specific pathogen free (SPF) 
chicks (lacking maternal antibodies), starting at 3 weeks 
of age (when immune function has matured) and follow-
ing serum antibody responses. In contrast, the protective 
efficacy of this antigen for reducing cecal colonization 
of broiler chicks was assessed by vaccinating commer-
cial broiler chicks (having maternal antibodies) with two 
doses of vaccine (at 1 and 3  weeks of age), followed by 
experimental challenge at 4 weeks of age. Thus immuno-
genicity was tested under conditions favorable to induc-
tion of antibody responses, but protective efficacy was 
tested in commercial chicks using earlier vaccination, 




Capsular polysaccharide of C. jejuni strain 81-176 was 
purified and conjugated to diphtheria toxoid CRM197 
to form capsular polysaccharide conjugate (CPSconj) as 
described previously [17].
Immunogenicity in the absence of maternal antibodies
Specific pathogen free chicks (SPF, N2 strain, Cornell 
University Center for Animal Resources and Educa-
tion, Cornell, New York, USA, 5 chicks per experimen-
tal group), lacking detectable maternal antibodies at the 
time of vaccination, were raised in the isolation facili-
ties of the Ontario Veterinary College and vaccinated 
subcutaneously at 3 and 4  weeks of age with 10  μg 
CPSconj with either 20 μg Quil A (Brenntag Biosector, 
Frederickssund, Denmark) or 10 μg CpG oligodeoxynu-
cleotide (CpG ODN) 2007 (Eurofins Operon, Huntsville, 
AL, USA) as adjuvants, or received 20 μg CPSconj with 
20 μg Quil A at 3, 4 and 5 weeks of age. Vaccination of 
these chicks thus occurred under favorable conditions 
(absence of maternal antibodies) beginning at an age 
when immune function is considered to be mature [27, 
28]. Control (placebo) birds received phosphate buffered 
saline (PBS) in place of vaccine.
Vaccination and challenge of commercial broiler chicks
One-day-old female commercial broiler chicks (Ross 308 
chicks from Stratford Chick Hatchery, Stratford, ON, 
Canada) were housed in isolation facilities at the Ontario 
Veterinary College. Chicks were allocated (8 chicks per 
group) to receive 25  μg CPSconj with 10  μg CpG or 
100  μl Addavax™ (squalene based adjuvant, InvivoGen, 
San Diego, CA, USA) as adjuvant, or 25  μg CPSconj 
without adjuvant, or PBS as a placebo by subcutaneous 
injection in a 200 μl volume at 7 days post-hatch. Birds 
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received a booster dose of 10  μg of the same antigen 
preparation as previously, or PBS at 21 days post-hatch. 
In contrast to the chicks used in the immunogenicity 
experiment above, these broiler chicks were obtained 
from a commercial source and had detectable serum 
(maternal) antibodies at the time of primary vaccination. 
At 29 days post-hatch birds were challenged orally with 
2 ×  107 CFU of C. jejuni strain 81-176 prepared by the 
method of Davis and DiRita [30] (see below). Birds were 
necropsied at 9 days post-challenge (38 days post-hatch) 
and dilutions of the cecal contents were plated onto 
Mueller–Hinton agar containing Preston Campylobacter 
Selective Supplement (Oxoid, Basingstoke, Hampshire, 
UK) and incubated at 42°C for 48  h in a microaerobic 
environment to quantitate CFU of C. jejuni. CFU per 
gram of cecal contents were calculated based on plate 
counts, adjusting for dilutions. An additional eight birds 
(serving as negative controls for challenge) were housed 
in a separate isolation room, were not vaccinated and 
were not challenged, but were necropsied at the same 
time as challenged birds. Blood was collected at 7, 21, 
29, 34 and 38  days post-hatch for serological testing. 
The experiment was repeated a second time using chicks 
from the same source, following the identical protocol in 
the same facilities, and the results were pooled for statis-
tical analysis.
Animal ethics
All experiments were approved by the Animal Care Com-
mittee of the University of Guelph (Animal Utilization 
Protocol number 10R086-1836) and followed the guide-
lines of the Canadian Council on Animal Care.
Enzyme‑linked immunosorbent assay (ELISA) for serum 
IgG antibodies
Purified capsular polysaccharide of C. jejuni diluted to 
40  μg/ml in PBS buffer was coated onto Nunc 96 well 
(MicroWell™ untreated polystyrene, Thermo Fisher Sci-
entific, Rochester, New York, USA) plates, 100  μl/well, 
at 37°C for 3  h. Plates were washed four times with 
wash buffer consisting of PBS with 0.5% fish skin gela-
tin (Sigma, St. Louis, MO, USA) and 0.05% Tween 20 
(Sigma). Sera were diluted 1/20 in wash buffer and 100 μl 
was added to wells in duplicate, followed by a 2 h incu-
bation at 37°C. After washing four times, bound anti-
bodies were detected using rabbit anti-chicken IgG (Fc 
specific) horse radish peroxidase conjugate (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) 
diluted 1/350, incubating at 37°C for 1 h. After washing 
four times, ABTS (2,2′-azino-di (3-ethyl-benzthiazoline-
6-sulfonate)) substrate (Kirkegaard and Perry Laborato-
ries, Gaithersburg, Maryland, USA) was added, 100 μl/
well; 1% sodium dodecylsulfate (Bio-Rad, Hercules, CA, 
USA) was added as stop solution after 1 h and the optical 
densities were evaluated at 405 nm. A dilution series of 
a positive control serum consisting of pooled high titre 
sera from mature hens was run on each plate. Titres were 
estimated using the method of Sacks et al. [31]. The limit 
of detection of the assay was 3.32 log2 units.
Bacterial culture
Campylobacter jejuni strain 81-176 was cultured accord-
ing to the method of Davis and DiRita [30] to provide bac-
teria for experimental oral challenge. Briefly, a 10-μL loop 
of frozen C. jejuni culture maintained at −80°C, was inoc-
ulated onto Mueller–Hinton agar (Oxoid) and incubated 
for 18 h in a sealed jar using gas packs (CampyGen, Oxoid) 
to maintain microaerobic conditions. Subsequently, sev-
eral colonies of C. jejuni were inoculated into 100  mL 
fresh Mueller–Hinton broth and incubated at 41°C in 
microaerobic conditions for 40  h. The broth culture was 
centrifuged at 3,500×g for 10  min and the bacteria were 
diluted with PBS (pH 7.4) to attain an optical density cor-
responding to approximately 4.0 × 107 CFU/ml, based on 
previous analysis of growth curves. The number of viable 
C. jejuni received by the chickens at the time of challenge 
was established retrospectively by plating dilutions of the 
inocula onto Mueller–Hinton agar plates.
Statistical analysis
Data from the two challenge trials were pooled. CFU/
gm of C. jejuni in cecal contents were log10 transformed 
before analysis using a mixed model (Proc Mixed) includ-
ing trial as a random variable, in SAS version 9.2. Vac-
cine groups were subsequently compared using Tukey’s 
test. Antibody titres were expressed on a log2 scale. Titres 
were not normally distributed for the majority of time 
points; a nonparametric test (Proc Npar1way [Kruskal–
Wallis test]) was used to compare antibody titres among 
groups. Seroconversion (increase in titre by ≥2 log2 
units) rates were compared using Fisher’s exact test. Cor-
relation between serum antibody titres on the day of 
necropsy and CFU of C. jejuni in cecal contents was eval-
uated using Pearson’s correlation coefficient using Proc 
Corr in SAS.
Results and discussion
Immunogenicity of the CPS conjugate vaccine  
in the absence of maternal antibodies
Mean serum IgG antibody titres increased in vaccinated 
SPF birds, but not in negative control birds that received 
PBS (Figure 1). Seroconversion rates were 20, 40 and 75% 
by 6 weeks of age in birds receiving two doses of CPSconj 
vaccine with CpG, two doses CPSconj with Quil A and 
three doses CPSconj with Quil A respectively. The sero-
conversion rate in birds receiving three doses of CPSconj 
Page 4 of 8Hodgins et al. BMC Res Notes  (2015) 8:204 
was significantly higher than the rate in birds receiving 
PBS as placebo (p < 0.05, one-tailed Fisher’s exact test).
Antibody responses of commercial broiler chicks
Maternal IgG antibodies were evident in serum at 7 days 
post-hatch at the time of primary vaccination, but 
declined considerably by day 21 (day of secondary vacci-
nation, Figure 2). Maternal antibodies have been shown 
to mediate partial protection against colonization by C. 
jejuni [32], but the short half-life of maternal antibodies 
(about 5  days in young chicks [33]) suggests that titres 
of maternal antibodies would need to be considerably 
higher to provide protection up to slaughter age. Mean 
serum IgG antibody titres declined further by day of chal-
lenge (day 29) in all groups. IgG antibody titres did not 
differ significantly among the four experimental groups 
(three groups of vaccinates and one placebo group) at any 
of the time points (Kruskal–Wallis test). Data from the 
vaccinated groups (CPS conjugate without adjuvant, CPS 
conjugate with Addavax™ adjuvant and CPS conjugate 
with CpG as adjuvant) were pooled for further analysis 
since there were no significant differences among them.
In Figure  3 the distribution of serum IgG antibody 
titres in vaccinated broiler birds and birds receiving pla-
cebo, is contrasted by means of histograms. Seroconver-
sion (an increase of titre ≥2 log2 units) was not detected 
before day of challenge in vaccinates. This is in contrast 
to responses seen in SPF birds by 3 weeks post primary 
vaccination (Figure 1). Seroconversion occurred in 33% of 
vaccinated broiler birds by 9 days post-challenge, but in 
none of the birds that had received placebo before chal-
lenge (p < 0.01, Fisher’s exact two-tailed test). This sug-
gests that although vaccination with two doses of vaccine 
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Figure 1 Immunogenicity of the capsular polysaccharide-diphtheria toxoid (CRM197) conjugate vaccine. Specific pathogen free chicks (N2 strain), 
lacking maternal antibodies at the time of primary vaccination, were vaccinated subcutaneously at 3 and 4 weeks post-hatch (10 μg of conjugate 
with 10 μg CpG or with 20μg Quil A), or at 3, 4 and 5 weeks post-hatch (20 μg of conjugate with 20 μg Quil A) or received phosphate buffered 
saline (PBS) as a placebo. Mean serum IgG antibodies specific for capsular polysaccharide of C. jejuni strain 81-176 were assayed by ELISA and titres 
were expressed on a log2 scale. The limit of detection was 3.32 (log2 scale). Seroconversion [fourfold or greater increase in antibody titre (≥2 log2 
units)] rates after vaccination are indicated on the right of the figure for each group. * Seroconversion rate was significantly higher than in birds 
receiving PBS as placebo (p < 0.05, one-tailed Fisher’s exact test).
































Figure 2 Mean serum IgG antibody titres to capsular polysaccharide 
of C. jejuni strain 81-176. Serum antibody titres were determined by 
ELISA. Error bars represent the standard error of the mean. At no point 
in time did the titres differ significantly among the experimental 
groups (Kruskal–Wallis nonparametric test). By the day of necropsy 
(day 38, 9 days post-challenge) 33% of vaccinated birds and 0% of 
PBS placebo birds had seroconverted with a four-fold or greater 
increase in antibody titre (≥2 log2 units), (see Figure 3).
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before the day of challenge, there was a degree of prim-
ing for anamnestic antibody responses (which occurred 
after exposure to live C. jejuni) in some of the birds. In 
a similar fashion, Siegrist et  al. [34] have reported an 
absence of serum antibody responses to vaccination in 
neonatal mice with circulating maternal antibodies. In 
these mouse experiments anamnestic antibody responses 
became evident after subsequent antigen exposure.
It is possible that if cecal CFU were monitored beyond 
9 days post-challenge, that mean CFU would decline fur-
ther as immune responses aided in clearance of C. jejuni. 
A gradual decline in cecal colonization in birds vacci-
nated with live attenuated Salmonella expressing the 
CjaA protein of C. jejuni has been reported by Buckley 
et al. [14]. Any decline after 5–6 weeks of age, however, 
is not relevant since most broiler birds are slaughtered 
by that age. Clearly further research will be needed to 
improve the immunogenicity of the vaccine for young 
broilers.
The lower seroconversion rates noted in commercial 
broiler chicks compared to SPF N strain birds are most 
probably due to the younger age at primary vaccination 
of the broilers, or to suppressive effects of residual mater-
nal antibodies, but the effect of different genetic back-
grounds cannot be eliminated as a factor in the current 
study.
Reduction in C. jejuni in cecal contents 
of vaccinated chicks
Colony-forming units of C. jejuni were significantly lower 
in the cecal contents of birds receiving CPSconj vaccine 
(with or without adjuvant) compared to control birds 
receiving PBS (Table 1). Mean CFU of C. jejuni did not 
differ significantly among groups of vaccinated birds and 
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Figure 3 Histograms showing distribution of serum IgG antibodies 
specific for capsular polysaccharide of C. jejuni strain 81-176 in com-
mercial broiler chicks. Chicks were vaccinated at 7 and 21 days post-
hatch with capsular polysaccharide-conjugate (with CpG ODN 2007, 
or Addavax™ as adjuvant, or no adjuvant; antibody titres for the three 
vaccinated groups were pooled to graph the histograms since they 
did not differ significantly at any of the time points) or received PBS 
placebo. IgG antibody titres were determined by ELISA and analyzed 
using the Kruskal–Wallis (nonparametric) test because at the majority 
of time points, the titres were not normally distributed. In each panel, 
the percentage (Y-axis) of (vaccinated and PBS control) birds with par-
ticular antibody titres is plotted against their titres at that time point. 
A shift (to the left) in the distribution of antibody titres, consistent with 
decline in titres of maternal antibodies, is evident from day 7 post-
hatch to day 29 (day of challenge), followed by a shift to the right after 
challenge. Antibody titres did not differ significantly among the four 
treatment groups at any of the time points. Seroconversion, a fourfold 
or greater (≥2 log2 units) increase in antibody titre, did not occur in 
any of the birds before the day of challenge (day 29 post-hatch), but 
33% of vaccinated and 0% of placebo (PBS) birds seroconverted by 
day 38 (9 days post-challenge, a significant difference, Fisher’s exact 
test p < 0.01). For each time point, sera from 14 to 16 PBS (placebo) 
birds and sera from 40 to 43 vaccinated birds were assayed.
Page 6 of 8Hodgins et al. BMC Res Notes  (2015) 8:204 
were pooled for further analysis. Vaccinated birds had a 
mean reduction in cecal C. jejuni of 0.64 log10 units com-
pared to birds receiving PBS as placebo (p < 0.001). There 
was essentially no correlation between serum antibody 
titres and cecal counts of C. jejuni at necropsy (r value of 
−0.06 among vaccinates with p = 0.70, data not shown). 
Since Campylobacter colonize the mucus layer of the 
intestinal tract and are rarely found in extra-intestinal 
sites, a low correlation between serum antibody titres 
and protection could be anticipated. Assay of antibodies 
in intestinal mucus should be more informative. Vacci-
nation with CPSconj by a mucosal route might improve 
vaccine efficacy compared to the subcutaneous route 
used in the present study, by inducing IgA antibodies at 
sites of colonization by C. jejuni. The subcutaneous route 
was used in the present study to assess immunogenic-
ity of the vaccine construct and to provide a baseline for 
comparison as systems for delivery to mucosal sites are 
developed. Rosenquist et  al. [35] have suggested, based 
on mathematical modeling, that a 2.0 log10 unit reduc-
tion in C. jejuni in chickens at slaughter would reduce 
clinical illness in humans 30-fold. Buckley et al. [14] have 
reported reductions in cecal colonization of 1.57–1.91 
log10 CFU of C. jejuni per gram of cecal contents in SPF 
chickens (lacking maternal antibodies) vaccinated with 
recombinant CjaA protein, but reductions were not 
evident until 7  weeks of age. Widders et  al. [11] have 
reported reductions of 1.9 log10 CFU per gram of cecal 
contents by 6 weeks of age in birds vaccinated intraperi-
toneally with antigens of killed C. jejuni. Larger reduc-
tions in cecal counts of C. jejuni (6 log10 CFU per gram) 
have been reported with Salmonella vectored vaccines 
[12], but there are safety issues associated with persis-
tence of the Salmonella vector in vaccinated birds [14].
A previous study vaccinating mature monkeys (lacking 
pre-existing antibody titres) with a CPSconj vaccine has 
demonstrated efficacy in reducing clinical signs (in pri-
mates), but quantitative studies of intestinal carriage of C. 
jejuni were not carried out [17]. Because C. jejuni causes 
clinical disease in primates, the end goal of vaccination in 
such studies is reduction in signs of disease. In contrast 
the goal in vaccinating chickens is to reduce the number 
of C. jejuni in the intestinal tract of the birds at the time 
of slaughter. This may require a qualitatively different 
or quantitatively greater immune response and will be a 
more elusive goal.
Alternative vaccination approaches
The current study assessed immunogenicity of the cap-
sular polysaccharide antigen conjugated to diphtheria 
toxoid CRM197. This carrier protein has been used in vac-
cines for human infants and has been shown to enhance 
immune responses to polysaccharide antigens in the first 
months of life [26]. Other carrier proteins have been 
used in conjugate vaccines [36] and perhaps these or 
even C. jejuni surface proteins may also prove efficacious 
in chickens. Schijns et  al. [37] have reported that some 
adjuvants enhance the immunogenicity of tetanus toxoid 
in immunologically mature chickens (3  weeks-old) but 
fail to induce antibodies to this antigen in day-old chicks, 
whereas other adjuvants are effective at both ages. Thus 
it may be necessary to optimize both carrier protein and 
adjuvant to produce conjugate vaccines immunogenic for 
day-old chicks.
In the present study vaccines were administered sub-
cutaneously to evaluate immunogenicity of the capsu-
lar antigen. Mucosal vaccination, especially by the oral 
route may be more effective to induce intestinal immune 
responses and reduce intestinal colonization, but 
improved adjuvants and delivery systems will be required 
to make this approach practical.
Further studies will be needed to optimize adjuvants, 
route of delivery, and scheduling of administration for 
use of CPSconj antigen in broiler chickens. Studies using 
heterologous challenge strains of C. jejuni are also in 
order.
Conclusions
A capsular polysaccharide—diphtheria toxoid conjugate 
vaccine administered subcutaneously, starting at 3  weeks 
Table 1 Colony-forming units of C. jejuni per gram of cecal contents 9 days post-challenge
Combined results from two experiments using Ross 308 broiler chicks from the same source and following the same experimental protocol. Chickens were vaccinated 
subcutaneously at 7 and 21 days post-hatch with capsular polysaccharide conjugate vaccine with or without CpG or Addavax™ as adjuvant, or received PBS as a pla-
cebo. Birds were challenged at 29 days post-hatch and necropsied at 38 days post-hatch.
Vaccine group n CFU per gram of cecal  
contents (log10 transformed)
Standard error  
of the mean
p value for comparison  
with the PBS group
PBS 16 8.11 0.15
Conjugate alone 13 7.38 0.16 0.01
Conjugate + CpG 14 7.55 0.15 <0.05
Conjugate + Addavax™ 16 7.47 0.14 0.01
All vaccinates (data pooled) 43 7.47 0.09 <0.001
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of age, induced serum IgG antibodies in SPF chicks lack-
ing detectable maternal antibodies. Vaccination of broiler 
chicks (that had maternal antibodies) starting at 7  days 
post-hatch was not associated with seroconversion with 
IgG antibodies before challenge at 29  days post-hatch. 
Some (33%) of the vaccinated broiler birds seroconverted 
by 9  days post-challenge, but none of the PBS (placebo) 
birds, indicating that the vaccine primed for an earlier IgG 
antibody response following challenge. There was a modest 
(0.64 log10 colony forming units) but significant (p < 0.001) 
reduction in C. jejuni in cecal contents, 9 days post-chal-
lenge, in vaccinated birds compared to negative control 
(placebo) birds. Further studies are needed to optimize 
adjuvant, route of delivery and scheduling of administra-
tion to make the most effective use of this vaccine antigen.
Abbreviations
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cleotide; CPSconj: capsular polysaccharide-diphtheria toxoid conjugate; SPF: 
specific pathogen free.
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